Vaccines Market Size, Share, Trends, Growth Outlook

Vaccines Market is estimated to increase at a Compounded Annual Growth Rate of 5.2% CAGR over the forecast period from 2024 to 2030

The Vaccines Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Technology (Conjugate Vaccines, Recombinant Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Viral Vector Vaccines, m-RNA Vaccines, Others), By Type (Monovalent Vaccines, Mulitvalent Vaccines), By Disease (Pneumococcal Disease, Influenza, Combination Vaccines, HPV, Meningococcal Disease, Herpes Zoster, Rotavirus, MMR, Varicella, Hepatitis, DTP, Polio, Others), By Route of Administration (Intramuscular, Subcutaneous, Oral, Others), By End-User (Pediatric Vaccine, Adult Vaccine).

An Introduction to Vaccines Market in 2024

Vaccines represent one of the most powerful tools in preventing infectious diseases, saving millions of lives worldwide each year. In 2024, the global vaccine market continues to expand, driven by technological advancements, growing public health awareness, and increased investment in vaccine research and development. From traditional attenuated and inactivated vaccines to cutting-edge mRNA and viral vector platforms, the diversity and efficacy of vaccines have never been greater. With the ongoing threat of pandemics and the emergence of novel pathogens, there is heightened emphasis on vaccine innovation, production scalability, and equitable distribution to ensure global health security. Moreover, efforts to address vaccine hesitancy, enhance immunization infrastructure, and tackle vaccine-preventable diseases remain at the forefront of public health agendas worldwide.

Market Trend: Development of mRNA and Vector-Based Vaccines

A prominent trend in the vaccines market is the increasing focus on the development and commercialization of mRNA vaccines and viral vector-based vaccines. Traditional vaccine approaches typically involve using weakened or inactivated pathogens to stimulate an immune response. However, mRNA vaccines, such as those against COVID-19, utilize genetic material to instruct cells to produce a viral antigen, triggering an immune response. Similarly, viral vector vaccines use modified viruses to deliver genetic material encoding the antigen into cells, prompting the immune system to mount a defense. These innovative vaccine platforms offer advantages such as rapid development, scalability, and potential for targeting a wide range of diseases, driving market growth and fostering innovation in vaccine research and development.

Market Driver: Global Immunization Initiatives and Pandemic Preparedness

A key driver propelling the growth of the vaccines market is the increasing emphasis on global immunization initiatives and pandemic preparedness efforts. With the rise of infectious disease outbreaks, such as the COVID-19 pandemic, there is heightened awareness of the importance of vaccination in preventing and controlling the spread of contagious diseases. Governments, public health organizations, and international agencies are prioritizing vaccine research, procurement, and distribution to achieve widespread immunization coverage and mitigate the impact of pandemics. Additionally, routine immunization programs targeting childhood diseases, influenza, HPV, and other vaccine-preventable illnesses continue to drive demand for vaccines globally. This driver underscores the critical role of vaccines in public health and healthcare systems, fueling market growth and investment in vaccine development and distribution infrastructure.

Market Opportunity: Expansion of Vaccine Manufacturing Capacity and Accessibility

An emerging opportunity in the vaccines market lies in the expansion of vaccine manufacturing capacity and accessibility to address global health challenges and ensure equitable vaccine distribution. The COVID-19 pandemic highlighted the need for scalable and resilient vaccine production capabilities to meet surging demand during public health emergencies. Manufacturers have an opportunity to invest in expanding manufacturing facilities, adopting innovative production technologies, and establishing partnerships to accelerate vaccine production timelines and increase supply capacity. Moreover, there is potential for improving vaccine distribution networks, cold chain infrastructure, and last-mile delivery systems to reach underserved populations in remote or resource-limited areas. By enhancing vaccine accessibility and affordability, stakeholders can strengthen global immunization efforts, reduce health disparities, and advance progress towards achieving universal health coverage and disease prevention goals.

Vaccines Market Share Analysis: mRNA Vaccines is the fastest growing segment over the forecast period to 2030

mRNA vaccines have emerged as one of the fastest-growing segments in the vaccines market due to their groundbreaking technology and demonstrated efficacy. Unlike traditional vaccines, which often use weakened or inactivated viruses to trigger an immune response, mRNA vaccines work by introducing a small piece of the virus's genetic material into the body, instructing cells to produce a protein that triggers an immune response. This approach offers several advantages, including faster development timelines, scalability, and potential for rapid adaptation to new variants. The recent success of mRNA vaccines, such as those developed for COVID-19, has propelled this segment into the spotlight, paving the way for expanded applications beyond infectious diseases, including cancer immunotherapy and personalized medicine. With ongoing research and investment in mRNA vaccine technology, this segment is poised for exponential growth and is to revolutionize the field of vaccinology in the coming years.

Vaccines Competitive Analysis

The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech International Ltd, Bio Farma, Biological E Ltd, CSL Ltd, Daiichi Sankyo Company Ltd, Emergent BioSolutions Inc, FSUE NPO Microgen, GlaxoSmithKline plc, Indian Immunologicals Ltd, Inovio Pharmaceuticals Inc, Johnson & Johnson Services Inc, Merck & Co. Inc, Mitsubishi Tanabe Pharma Corp, Novavax Inc, Panacea Biotec Ltd, Pfizer Inc, Sanofi SA, Serum Institute of India Private Ltd, Sinovac Incepta Pharmaceuticals, Valneva SE, VBI Vaccines Inc, Zhi Fei Biological Products Co. Ltd

Vaccines Market Segmentation

By Technology
Conjugate Vaccines
Recombinant Vaccines
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Viral Vector Vaccines
m-RNA Vaccines
Others
By Type
Monovalent Vaccines
Mulitvalent Vaccines
By Disease
Pneumococcal Disease
Influenza
Combination Vaccines
HPV
Meningococcal Disease
Herpes Zoster
Rotavirus
MMR
Varicella
Hepatitis
DTP
Polio
Others
By Route of Administration
Intramuscular
Subcutaneous
Oral
Others
By End-User
Pediatric Vaccine
Adult Vaccine
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Vaccines Market Companies

AstraZeneca PLC
Bavarian Nordic A/S
Bharat Biotech International Ltd
Bio Farma
Biological E Ltd
CSL Ltd
Daiichi Sankyo Company Ltd
Emergent BioSolutions Inc
FSUE NPO Microgen
GlaxoSmithKline plc
Indian Immunologicals Ltd
Inovio Pharmaceuticals Inc
Johnson & Johnson Services Inc
Merck & Co. Inc
Mitsubishi Tanabe Pharma Corp
Novavax Inc
Panacea Biotec Ltd
Pfizer Inc
Sanofi SA
Serum Institute of India Private Ltd
Sinovac Incepta Pharmaceuticals
Valneva SE
VBI Vaccines Inc
Zhi Fei Biological Products Co. Ltd

Reasons to Buy the Vaccines Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Vaccines Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Vaccines Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Vaccines Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Vaccines Market Size Outlook, $ Million, 2021 to 2030
3.2 Vaccines Market Outlook by Type, $ Million, 2021 to 2030
3.3 Vaccines Market Outlook by Product, $ Million, 2021 to 2030
3.4 Vaccines Market Outlook by Application, $ Million, 2021 to 2030
3.5 Vaccines Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Vaccines Industry
4.2 Key Market Trends in Vaccines Industry
4.3 Potential Opportunities in Vaccines Industry
4.4 Key Challenges in Vaccines Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Vaccines Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Vaccines Market Outlook by Segments
7.1 Vaccines Market Outlook by Segments, $ Million, 2021- 2030
By Technology
Conjugate Vaccines
Recombinant Vaccines
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Viral Vector Vaccines
m-RNA Vaccines
Others
By Type
Monovalent Vaccines
Mulitvalent Vaccines
By Disease
Pneumococcal Disease
Influenza
Combination Vaccines
HPV
Meningococcal Disease
Herpes Zoster
Rotavirus
MMR
Varicella
Hepatitis
DTP
Polio
Others
By Route of Administration
Intramuscular
Subcutaneous
Oral
Others
By End-User
Pediatric Vaccine
Adult Vaccine

8 North America Vaccines Market Analysis and Outlook To 2030
8.1 Introduction to North America Vaccines Markets in 2024
8.2 North America Vaccines Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Vaccines Market size Outlook by Segments, 2021-2030
By Technology
Conjugate Vaccines
Recombinant Vaccines
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Viral Vector Vaccines
m-RNA Vaccines
Others
By Type
Monovalent Vaccines
Mulitvalent Vaccines
By Disease
Pneumococcal Disease
Influenza
Combination Vaccines
HPV
Meningococcal Disease
Herpes Zoster
Rotavirus
MMR
Varicella
Hepatitis
DTP
Polio
Others
By Route of Administration
Intramuscular
Subcutaneous
Oral
Others
By End-User
Pediatric Vaccine
Adult Vaccine

9 Europe Vaccines Market Analysis and Outlook To 2030
9.1 Introduction to Europe Vaccines Markets in 2024
9.2 Europe Vaccines Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Vaccines Market Size Outlook by Segments, 2021-2030
By Technology
Conjugate Vaccines
Recombinant Vaccines
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Viral Vector Vaccines
m-RNA Vaccines
Others
By Type
Monovalent Vaccines
Mulitvalent Vaccines
By Disease
Pneumococcal Disease
Influenza
Combination Vaccines
HPV
Meningococcal Disease
Herpes Zoster
Rotavirus
MMR
Varicella
Hepatitis
DTP
Polio
Others
By Route of Administration
Intramuscular
Subcutaneous
Oral
Others
By End-User
Pediatric Vaccine
Adult Vaccine

10 Asia Pacific Vaccines Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Vaccines Markets in 2024
10.2 Asia Pacific Vaccines Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Vaccines Market size Outlook by Segments, 2021-2030
By Technology
Conjugate Vaccines
Recombinant Vaccines
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Viral Vector Vaccines
m-RNA Vaccines
Others
By Type
Monovalent Vaccines
Mulitvalent Vaccines
By Disease
Pneumococcal Disease
Influenza
Combination Vaccines
HPV
Meningococcal Disease
Herpes Zoster
Rotavirus
MMR
Varicella
Hepatitis
DTP
Polio
Others
By Route of Administration
Intramuscular
Subcutaneous
Oral
Others
By End-User
Pediatric Vaccine
Adult Vaccine

11 South America Vaccines Market Analysis and Outlook To 2030
11.1 Introduction to South America Vaccines Markets in 2024
11.2 South America Vaccines Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Vaccines Market size Outlook by Segments, 2021-2030
By Technology
Conjugate Vaccines
Recombinant Vaccines
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Viral Vector Vaccines
m-RNA Vaccines
Others
By Type
Monovalent Vaccines
Mulitvalent Vaccines
By Disease
Pneumococcal Disease
Influenza
Combination Vaccines
HPV
Meningococcal Disease
Herpes Zoster
Rotavirus
MMR
Varicella
Hepatitis
DTP
Polio
Others
By Route of Administration
Intramuscular
Subcutaneous
Oral
Others
By End-User
Pediatric Vaccine
Adult Vaccine
12 Middle East and Africa Vaccines Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Vaccines Markets in 2024
12.2 Middle East and Africa Vaccines Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Vaccines Market size Outlook by Segments, 2021-2030
By Technology
Conjugate Vaccines
Recombinant Vaccines
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Viral Vector Vaccines
m-RNA Vaccines
Others
By Type
Monovalent Vaccines
Mulitvalent Vaccines
By Disease
Pneumococcal Disease
Influenza
Combination Vaccines
HPV
Meningococcal Disease
Herpes Zoster
Rotavirus
MMR
Varicella
Hepatitis
DTP
Polio
Others
By Route of Administration
Intramuscular
Subcutaneous
Oral
Others
By End-User
Pediatric Vaccine
Adult Vaccine

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AstraZeneca PLC
Bavarian Nordic A/S
Bharat Biotech International Ltd
Bio Farma
Biological E Ltd
CSL Ltd
Daiichi Sankyo Company Ltd
Emergent BioSolutions Inc
FSUE NPO Microgen
GlaxoSmithKline plc
Indian Immunologicals Ltd
Inovio Pharmaceuticals Inc
Johnson & Johnson Services Inc
Merck & Co. Inc
Mitsubishi Tanabe Pharma Corp
Novavax Inc
Panacea Biotec Ltd
Pfizer Inc
Sanofi SA
Serum Institute of India Private Ltd
Sinovac Incepta Pharmaceuticals
Valneva SE
VBI Vaccines Inc
Zhi Fei Biological Products Co. Ltd

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Technology
Conjugate Vaccines
Recombinant Vaccines
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Viral Vector Vaccines
m-RNA Vaccines
Others
By Type
Monovalent Vaccines
Mulitvalent Vaccines
By Disease
Pneumococcal Disease
Influenza
Combination Vaccines
HPV
Meningococcal Disease
Herpes Zoster
Rotavirus
MMR
Varicella
Hepatitis
DTP
Polio
Others
By Route of Administration
Intramuscular
Subcutaneous
Oral
Others
By End-User
Pediatric Vaccine
Adult Vaccine
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)